Eikon Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-309.52	-243.81	-242
Depreciation & Amortization	25.29	25.39	17.75
Asset Writedown & Restructuring Costs	21.02	-	35
Loss (Gain) From Sale of Investments	-6.11	-9.46	-21.11
Stock-Based Compensation	17.35	12.43	9.54
Change in Accounts Payable	-0.11	2.95	0.24
Change in Other Net Operating Assets	81.55	77.7	9.74
Operating Cash Flow	-170.53	-134.8	-190.85
Capital Expenditures	-86.19	-84.8	-28.51
Investment in Securities	-127.71	236.15	165.46
Investing Cash Flow	-213.9	151.35	136.95
Issuance of Common Stock	0.91	0.24	0.4
Financing Cash Flow	351.06	0.24	105.81
Net Cash Flow	-33.37	16.8	51.91
Free Cash Flow	-256.73	-219.6	-219.36
Free Cash Flow Per Share	-91.50	-87.16	-108.26
Cash Interest Paid	0.89	0.03	0.04
Levered Free Cash Flow	-	-190.73	-
Unlevered Free Cash Flow	-	-190.71	-
Change in Working Capital	81.44	80.65	9.98

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q